230 related articles for article (PubMed ID: 16880774)
1. Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB.
Carter LP; Richards BD; Mintzer MZ; Griffiths RR
Neuropsychopharmacology; 2006 Nov; 31(11):2537-51. PubMed ID: 16880774
[TBL] [Abstract][Full Text] [Related]
2. Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects.
Carter LP; Griffiths RR; Suess PE; Casada JH; Wallace CL; Roache JD
J Pharmacol Exp Ther; 2007 Aug; 322(2):749-59. PubMed ID: 17502431
[TBL] [Abstract][Full Text] [Related]
3. Comparison of triazolam and pentobarbital: performance impairment, subjective effects and abuse liability.
Roache JD; Griffiths RR
J Pharmacol Exp Ther; 1985 Jul; 234(1):120-33. PubMed ID: 2861282
[TBL] [Abstract][Full Text] [Related]
4. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Johnson MW; Suess PE; Griffiths RR
Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
[TBL] [Abstract][Full Text] [Related]
5. Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers.
Carter LP; Griffiths RR; Mintzer MZ
Psychopharmacology (Berl); 2009 Sep; 206(1):141-54. PubMed ID: 19543883
[TBL] [Abstract][Full Text] [Related]
6. Dose-response evaluation of the amnestic effects of triazolam and pentobarbital in normal subjects.
Kirk T; Roache JD; Griffiths RR
J Clin Psychopharmacol; 1990 Jun; 10(3):160-7. PubMed ID: 2198294
[TBL] [Abstract][Full Text] [Related]
7. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability.
Evans SM; Funderburk FR; Griffiths RR
J Pharmacol Exp Ther; 1990 Dec; 255(3):1246-55. PubMed ID: 2262904
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of triazolam and ethanol on awareness, memory, and psychomotor performance.
Roache JD; Cherek DR; Bennett RH; Schenkler JC; Cowan KA
J Clin Psychopharmacol; 1993 Feb; 13(1):3-15. PubMed ID: 8486815
[TBL] [Abstract][Full Text] [Related]
9. Response to, "Cognitive, psychomotor and subjective effects of sodium oxybate and triazolam in healthy volunteers," 2009; 206(1):141-154.
Zvosec DL; Smith SW
Psychopharmacology (Berl); 2009 Dec; 207(3):509-10; author reply 511-2. PubMed ID: 19777215
[No Abstract] [Full Text] [Related]
10. Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.
Zawertailo LA; Busto UE; Kaplan HL; Greenblatt DJ; Sellers EM
J Clin Psychopharmacol; 2003 Jun; 23(3):269-80. PubMed ID: 12826989
[TBL] [Abstract][Full Text] [Related]
11. Ethanol and pentobarbital: comparison of behavioral and subjective effects in sedative drug abusers.
Mintzer MZ; Guarino J; Kirk T; Roache JD; Griffiths RR
Exp Clin Psychopharmacol; 1997 Aug; 5(3):203-15. PubMed ID: 9260068
[TBL] [Abstract][Full Text] [Related]
12. Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers.
Hallam KT; Olver JS; McGrath C; Norman TR
Hum Psychopharmacol; 2003 Dec; 18(8):619-25. PubMed ID: 14696021
[TBL] [Abstract][Full Text] [Related]
13. Flunitrazepam and triazolam: a comparison of behavioral effects and abuse liability.
Mintzer MZ; Griffiths RR
Drug Alcohol Depend; 1998 Dec; 53(1):49-66. PubMed ID: 10933340
[TBL] [Abstract][Full Text] [Related]
14. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users.
Abanades S; Farré M; Barral D; Torrens M; Closas N; Langohr K; Pastor A; de la Torre R
J Clin Psychopharmacol; 2007 Dec; 27(6):625-38. PubMed ID: 18004131
[TBL] [Abstract][Full Text] [Related]
15. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics.
Abanades S; Farré M; Segura M; Pichini S; Barral D; Pacifici R; Pellegrini M; Fonseca F; Langohr K; De La Torre R
Ann N Y Acad Sci; 2006 Aug; 1074():559-76. PubMed ID: 17105953
[TBL] [Abstract][Full Text] [Related]
16. Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: II. Comparison with triazolam and caffeine in humans.
Rush CR; Madakasira S; Goldman NH; Woolverton WL; Rowlett JK
J Pharmacol Exp Ther; 1997 Jan; 280(1):174-88. PubMed ID: 8996195
[TBL] [Abstract][Full Text] [Related]
17. Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers.
Mintzer MZ; Frey JM; Yingling JE; Griffiths RR
Behav Pharmacol; 1997 Nov; 8(6-7):561-74. PubMed ID: 9832970
[TBL] [Abstract][Full Text] [Related]
18. Experimental assessment of the relative abuse liability of triazolam and pentobarbital.
Roache JD; Griffiths RR
NIDA Res Monogr; 1984; 55():106-10. PubMed ID: 6443368
[No Abstract] [Full Text] [Related]
19. Triazolam-amphetamine interaction: dissociation of effects on memory versus arousal.
Mintzer MZ; Griffiths RR
J Psychopharmacol; 2003 Mar; 17(1):17-29. PubMed ID: 12680736
[TBL] [Abstract][Full Text] [Related]
20. Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability.
Preston KL; Wolf B; Guarino JJ; Griffiths RR
J Pharmacol Exp Ther; 1992 Aug; 262(2):707-20. PubMed ID: 1501118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
